A new UK puberty blockers trial is set to begin, following last year’s ban on the treatment for children questioning their gender identity. This landmark study, led by King’s College London, will assess the safety and impact of puberty-blocking drugs on children under 16, who experience gender incongruence. The trial, named Pathway, aims to understand the physical, emotional, and social effects of the drugs.
Study to Involve 220 Children and Assess Multiple Aspects of Wellbeing
The trial will include around 220 children currently undergoing puberty, with the aim of evaluating the impact of puberty blockers on mental health, brain development, and physical wellbeing. Researchers will monitor the children’s progress, focusing on areas such as bone density, mental health, and social well-being. Participants will be carefully selected and undergo comprehensive medical and psychological evaluations before starting treatment.
Ethical Concerns and Legal Challenges
While some clinicians believe the trial will help improve healthcare for young people with gender incongruence, others question its ethics. Campaigners like Keira Bell, who previously challenged the use of puberty blockers in court, argue that the treatment remains unsafe for children and should not be administered. Legal proceedings may follow if the trial proceeds, with the potential for judicial review at the High Court.
The Importance of the Study and Its Future Implications
Prof Emily Simonoff, the study leader, emphasizes the need for more clinical data to guide decision-making for children experiencing gender distress. She stressed that the trial is not intended to offer a “one-size-fits-all” solution but to provide valuable insights into how puberty blockers affect children’s overall well-being. The first results are expected in approximately four years, providing crucial evidence to inform future gender treatment strategies.
